Open Access

Aripiprazole exerts a neuroprotective effect in mouse focal cerebral ischemia

  • Authors:
    • Chan H. Gil
    • Yu R. Kim
    • Hong J. Lee
    • Da H. Jung
    • Hwa K. Shin
    • Byung T. Choi
  • View Affiliations

  • Published online on: November 6, 2017     https://doi.org/10.3892/etm.2017.5443
  • Pages: 745-750
  • Copyright: © Gil et al. This is an open access article distributed under the terms of Creative Commons Attribution License.

Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )
Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )


Abstract

Previous studies have demonstrated that aripiprazole (APZ), a third‑generation atypical antipsychotic drug, exhibits anti‑depressant and neuroprotective effects by promoting dopaminergic neuronal cell recovery in stroke. To investigate the neuroprotective effects of APZ, behavioral and histopathological experiments were performed in the current study a mouse model of middle cerebral artery occlusion (MCAO)‑induced ischemia following administration of APZ. The subacute phase of ischemic assaults was divided into 3 periods, each with a duration of 5 days, according to the start of APZ (3 mg/kg) administration (1‑5, 5‑9 or 10‑14 days following MCAO). The beneficial effects of APZ on motor behavior demonstrated in the cylinder, rotarod and wire suspension tests were greatest when APZ was administered 1‑5 days following MCAO, with clear improvements in motor function compared with vehicle‑treated mice. Histopathological analysis revealed that prominent atrophic changes occurred in the striatum of MCAO mice and that these changes were reduced following APZ treatment. APZ also attenuated dopaminergic neuronal injury in the striatum. Cell death and microglial activation were decreased and the expression of Ca2+/calmodulin‑dependent protein kinase II δ was enhanced following APZ treatment. These results indicate that the atypical antipsychotic drug, APZ, exhibits a neuroprotective effect in dopaminergic neuronal cells that may improve behavioral function following ischemic stroke.

References

1 

Shapiro DA, Renock S, Arrington E, Chiodo LA, Liu LX, Sibley DR, Roth BL and Mailman R: Aripiprazole, a novel atypical antipsychotic drug with a unique and robust pharmacology. Neuropsychopharmacology. 28:1400–1411. 2003. View Article : Google Scholar : PubMed/NCBI

2 

Greenaway M and Elbe D: Focus on aripiprazole: A review of its use in child and adolescent psychiatry. J Can Acad Child Adolesc Psychiatry. 18:250–260. 2009.PubMed/NCBI

3 

Russo E, Citraro R, Davoli A, Gallelli L, Di Paola ED and De Sarro G: Ameliorating effects of aripiprazole on cognitive functions and depressive-like behavior in a genetic rat model of absence epilepsy and mild-depression comorbidity. Neuropharmacology. 64:371–379. 2013. View Article : Google Scholar : PubMed/NCBI

4 

Burda K, Czubak A, Kus K, Nowakowska E, Ratajczak P and Zin J: Influence of aripiprazole on the antidepressant, anxiolytic and cognitive functions of rats. Pharmacol Rep. 63:898–907. 2011. View Article : Google Scholar : PubMed/NCBI

5 

Kronenberg G, Gertz K, Heinz A and Endres M: Of mice and men: Modelling post-stroke depression experimentally. Br J Pharmacol. 171:4673–4689. 2014. View Article : Google Scholar : PubMed/NCBI

6 

Loubinoux I, Kronenberg G, Endres M, Schumann-Bard P, Freret T, Filipkowski RK, Kaczmarek L and Popa-Wagner A: Post-stroke depression: Mechanisms, translation and therapy. J Cell Mol Med. 16:1961–1969. 2012. View Article : Google Scholar : PubMed/NCBI

7 

Shimoda K and Kimura M: Two cases of emotional disorder after middle cerebral artery infarction showing distinct responses to antidepressant treatment. Neuropsychiatr Dis Treat. 10:965–970. 2014. View Article : Google Scholar : PubMed/NCBI

8 

Kim YR, Kim HN, Pak ME, Ahn SM, Hong KH, Shin HK and Choi BT: Studies on the animal model of post-stroke depression and application of antipsychotic aripiprazole. Behav Brain Res. 287:294–303. 2015. View Article : Google Scholar : PubMed/NCBI

9 

Kim YR, Kim HN, Hong KW, Shin HK and Choi BT: Antidepressant effects of aripiprazole augmentation for cilostazol-treated mice exposed to chronic mild stress after ischemic stroke. Int J Mol Sci. 18:pii: E3552017. View Article : Google Scholar

10 

Cosi C, Waget A, Rollet K, Tesori V and Newman-Tancredi A: Clozapine, ziprasidone and aripiprazole but not haloperidol protect against kainic acid-induced lesion of the striatum in mice, in vivo: Role of 5-HT1A receptor activation. Brain Res. 1043:32–41. 2005. View Article : Google Scholar : PubMed/NCBI

11 

Zhang Y, Chen Y, Wu J, Manaenko A, Yang P, Tang J, Fu W and Zhang JH: Activation of dopamine D2 receptor suppresses neuroinflammation through αB-crystalline by inhibition of NF-κB nuclear translocation in experimental ICH mice model. Stroke. 46:2637–2646. 2015. View Article : Google Scholar : PubMed/NCBI

12 

Hall ED, Andrus PK, Oostveen JA, Althaus JS and VonVoigtlander PF: Neuroprotective effects of the dopamine D2/D3 agonist pramipexole against postischemic or methamphetamine-induced degeneration of nigrostriatal neurons. Brain Res. 742:80–88. 1996. View Article : Google Scholar : PubMed/NCBI

13 

Koprivica V, Regardie K, Wolff C, Fernalld R, Murphy JJ, Kambayashi J, Kikuchi T and Jordan S: Aripiprazole protects cortical neurons from glutamate toxicity. Eur J Pharmacol. 651:73–76. 2011. View Article : Google Scholar : PubMed/NCBI

14 

Zaleska MM, Mercado ML, Chavez J, Feuerstein GZ, Pangalos MN and Wood A: The development of stroke therapeutics: Promising mechanisms and translational challenges. Neuropharmacology. 56:329–341. 2009. View Article : Google Scholar : PubMed/NCBI

15 

Hua Y, Schallert T, Keep RF, Wu J, Hoff JT and Xi G: Behavioral tests after intracerebral hemorrhage in the rat. Stroke. 33:2478–2484. 2002. View Article : Google Scholar : PubMed/NCBI

16 

Patil SP, Jain PD, Sancheti JS, Ghumatkar PJ, Tambe R and Sathaye S: Neuroprotective and neurotrophic effects of Apigenin and Luteolin in MPTP induced parkinsonism in mice. Neuropharmacology. 86:192–202. 2014. View Article : Google Scholar : PubMed/NCBI

17 

Taleb O, Bouzobra F, Tekin-Pala H, Meyer L, Mensah-Nyagan AG and Patte-Mensah C: Behavioral and electromyographic assessment of oxaliplatin-induced motor dysfunctions: Evidence for a therapeutic effect of allopregnanolone. Behav Brain Res. 320:440–449. 2017. View Article : Google Scholar : PubMed/NCBI

18 

Farlow MR and Shamliyan TA: Benefits and harms of atypical antipsychotics for agitation in adults with dementia. Eur Neuropsychopharmacol. 27:217–231. 2017. View Article : Google Scholar : PubMed/NCBI

19 

Kasteng F, Eriksson J, Sennfält K and Lindgren P: Metabolic effects and cost-effectiveness of aripiprazole versus olanzapine in schizophrenia and bipolar disorder. Acta Psychiatr Scand. 124:214–225. 2011. View Article : Google Scholar : PubMed/NCBI

20 

Citrome L, Kalsekar I, Baker RA and Hebden T: A review of real-world data on the effects of aripiprazole on weight and metabolic outcomes in adults. Curr Med Res Opin. 30:1629–1641. 2014. View Article : Google Scholar : PubMed/NCBI

21 

Khanna P, Suo T, Komossa K, Ma H, Rummel-Kluge C, El-Sayeh HG, Leucht S and Xia J: Aripiprazole versus other atypical antipsychotics for schizophrenia. Cochrane Database Syst Rev: CD006569. 2014. View Article : Google Scholar

22 

Zhu H, Zhang Y, Shi Z, Lu D, Li T, Ding Y, Ruan Y and Xu A: The neuroprotection of liraglutide against ischaemia-induced apoptosis through the activation of the PI3K/AKT and MAPK pathways. Sci Rep. 6:268592016. View Article : Google Scholar : PubMed/NCBI

23 

Park SW, Lee CH, Lee JG, Kim LW, Shin BS, Lee BJ and Kim YH: Protective effects of atypical antipsychotic drugs against MPP(+)-induced oxidative stress in PC12 cells. Neurosci Res. 69:283–290. 2011. View Article : Google Scholar : PubMed/NCBI

24 

Shioda N, Sawai M, Ishizuka Y, Shirao T and Fukunaga K: Nuclear translocation of calcium/calmodulin-dependent protein kinase IIδ3 promoted by protein phosphatase-1 enhances brain-derived neurotrophic factor in dopaminergic neurons. J Biol Chem. 290:21663–21675. 2015. View Article : Google Scholar : PubMed/NCBI

25 

Farber K, Pannasch U and Kettenmann H: Dopamine and noradrenaline control distinct functions in rodent microglial cells. Mol Cell Neurosci. 29:128–138. 2005. View Article : Google Scholar : PubMed/NCBI

26 

Shao W, Zhang SZ, Tang M, Zhang XH, Zhou Z, Yin YQ, Zhou QB, Huang YY, Liu YJ, Wawrousek E, et al: Suppression of neuroinflammation by astrocytic dopamine D2 receptors via αB-crystallin. Nature. 494:90–94. 2013. View Article : Google Scholar : PubMed/NCBI

27 

Huck JH, Freyer D, Böttcher C, Mladinov M, Muselmann-Genschow C, Thielke M, Gladow N, Bloomquist D, Mergenthaler P and Priller J: De novo expression of dopamine D2 receptors on microglia after stroke. J Cereb Blood Flow Metab. 35:1804–1811. 2015. View Article : Google Scholar : PubMed/NCBI

28 

Kato T, Mizoguchi Y, Monji A, Horikawa H, Suzuki SO, Seki Y, Iwaki T, Hashioka S and Kanba S: Inhibitory effects of aripiprazole on interferon-gamma-induced microglial activation via intracellular Ca2+ regulation in vitro. J Neurochem. 106:815–825. 2008. View Article : Google Scholar : PubMed/NCBI

Related Articles

Journal Cover

January 2018
Volume 15 Issue 1

Print ISSN: 1792-0981
Online ISSN:1792-1015

Sign up for eToc alerts

Recommend to Library

Copy and paste a formatted citation
APA
Gil, C.H., Kim, Y.R., Lee, H.J., Jung, D.H., Shin, H.K., & Choi, B.T. (2018). Aripiprazole exerts a neuroprotective effect in mouse focal cerebral ischemia. Experimental and Therapeutic Medicine, 15, 745-750. https://doi.org/10.3892/etm.2017.5443
MLA
Gil, C. H., Kim, Y. R., Lee, H. J., Jung, D. H., Shin, H. K., Choi, B. T."Aripiprazole exerts a neuroprotective effect in mouse focal cerebral ischemia". Experimental and Therapeutic Medicine 15.1 (2018): 745-750.
Chicago
Gil, C. H., Kim, Y. R., Lee, H. J., Jung, D. H., Shin, H. K., Choi, B. T."Aripiprazole exerts a neuroprotective effect in mouse focal cerebral ischemia". Experimental and Therapeutic Medicine 15, no. 1 (2018): 745-750. https://doi.org/10.3892/etm.2017.5443